Navigation Links
Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
Date:8/26/2009

new' target='_new' href="http://www.octapharma.com/corporate/02_the_company/02_people/01_management_board/01_management_board.php" target="_new">Kim Bjornstrup. "Our first therapies were developed for the hemophilia community and today most hemophilia patient advocates say that inhibitor development is the greatest obstacle to effective treatment. Octapharma is focused on introducing innovative development strategies that will help improve patient quality of life by finding an effective treatment and developing products to overcome this obstacle."

The Octapharma-sponsored symposium "Prevention and Eradication of FVIII Inhibitors: Bridging Lab and Field Research" was chaired by David Lillicrap, M.D., Professor of Pathology and Molecular Medicine at Queen's University in Ontario, Canada, and Georges E. Rivard, M.D., Professor of Pediatrics at Universite de Montreal. The symposium provided an opportunity for discussing recent data supporting the use of von Willebrand factor (VWF)/FVIII concentrates for Immune Tolerance Induction (ITI) in hemophilia A patients with poor prognosis for a successful ITI outcome.

Presenters reviewed a balanced mix of clinical, preclinical and basic data on the role of the presence of VWF in FVIII concentrates and the clinical experience on prevention and eradication of FVIII inhibitors. In addition, the most recent prospective and retrospective clinical data obtained with different classes of FVIII concentrates used for ITI treatment were presented along with an update on the progress of the ongoing prospective study designed to further investigate the risk of FVIII inhibitor development in previously untreated patients with hemophilia.

"A growing body of clinical experience suggests that VWF-containing pdFVIII concentrates increase the likelihood of successful tolerization, particularly in patients with poor prognostic factors," said symposium presenter Wolfh
'/>"/>

SOURCE Octapharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
2. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
3. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
4. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
8. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
9. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
10. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... today announced financial results for its first quarter ended ... months ended December 31, 2014, revenue was $1,336,685. Operating ... $229,820 or $0.02 per share.  Covalon,s ... am very pleased with the significant progress we have ...
(Date:2/27/2015)... 2015 ... kongestive Herzinsuffizienz (CHF) in seiner ersten klinischen ...   Die israelische Firma ... für Patienten mit kongestiver Herzinsuffizienz (CHF) entwickelt ... Finanzierungsvorhaben über 5 Mio. USD abgeschlossen hat. ...
(Date:2/27/2015)... , Feb. 27, 2015  Chiasma, Inc., a ... product for the orphan condition acromegaly, today announced the ... Participants in the financing included new investors Rock Springs ... public investment fund, as well as existing investors MPM ... ARCH Venture Partners. Chiasma intends to ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... recent study conducted by oculoplastic surgeon Charles Soparkar, ... a patent-pending formulation of zinc and phytase (trademarked ... oral administration for 4 days prior to a ... duration in 41 of 44 patients tested (93%). ...
... ABT ) announced today it has received approval from the U.S. ... e HBV assay for measuring viral load or the amount of ... first and only approved test capable of automating HBV viral load ... Abbott RealTi m e HBV assay, based on real-time PCR (polymerase ...
Cached Medicine Technology:Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results 2Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment 2Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment 3Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment 4
(Date:2/28/2015)... 28, 2015 The Heart Fit Clinic ... distributor of the machine. The Heart Fit Clinic is ... like a franchise model. The goal is to scale ... heart disease. To buy External Counterpulsation machines ... help individuals through this process and achieve the desired ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate ... provide business consulting services in addition to a variety ... and succession planning. Company finances are a complicated matter ... top of this, complex Canadian tax laws can make ... a result, Mew and Company works to advise their ...
(Date:2/28/2015)... A study out of the University ... procedure for the treatment of a hereditary ocular condition ... Authored by Dr. Robert MacLaren, professor of ophthalmology at ... Medical Journal on January 16, 2014 , the study ... disorder that mostly affects men and leads to the ...
(Date:2/28/2015)... Portland, OR (PRWEB) February 28, 2015 ... at the 2015 Japan Architecture & Construction Materials Show, ... They’ll join more than 1,000 suppliers and top manufacturers ... , Reclaimed wood products sourced and manufactured ... facilities have found popularity in Japan at restaurants, hotels, ...
(Date:2/28/2015)... FL (PRWEB) February 28, 2015 ... organization has sponsored visitor health insurance programs for visitors ... years. Most Indian elderly parents traveling to the United ... such as diabetes and blood pressure. These diseases are ... not even list them as medical conditions. There were ...
Breaking Medicine News(10 mins):Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
... Founder of ... who accelerated her recovery. Lack of friends connected to poorer health Company aims to reduce ... ... The Friendship Stone will mark Friendship Week starting August 2nd. Founder, Cathy Raff, will dedicate ...
... , , New Report Is ... Lower Costs , , KANSAS CITY, Mo., ... marks for communicating effectively and treating them respectfully, according to a new patient experience ... 700 doctors are available at http://kcq i c.org ...
... , , OLYMPIA, ... prescription medications since the launch of the free statewide prescription assistance program. ... was launched in August, 2008. The program has no restrictions to membership, ... fill out. Anyone interested in receiving a free card can visit ...
... , , WARSAW, Ind., July ... independent provider of products to the global orthopaedic device industry and other ... results for the period ending July 4, 2009 before the market opens ... call at 8:00 a.m. ET on Thursday, August 6, 2009. , ...
... , , HOUSTON, July 21 US Oncology, ... on Thursday, August 6, 2009. , , A ... ET following distribution of the earnings release. Additional information will be available on ... on the day of the earnings announcement. , , ...
... IHA Completes the Second Chapter of the ... for Measurement Years 2006 - 2009 , ... (IHA) is pleased to announce the publication of "The Second Chapter," a ... for performance (P4P) program - the largest non-governmental physician incentive program in ...
Cached Medicine News:Health News:The Friendship Stone Helps Friends Remain Healthy 2Health News:The Friendship Stone Helps Friends Remain Healthy 3Health News:The Friendship Stone Helps Friends Remain Healthy 4Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 2Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 3Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 4Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 5Health News:Free Drug Card Has Saved Washington Residents $2.6 Million 2Health News:Symmetry Medical to Report Second Quarter 2009 Financial Results on August 6, 2009 2Health News:US Oncology to Report 2009 Second Quarter Operating Results 2Health News:Integrated Healthcare Association Releases White Paper on Pay for Performance 2
Used with Single Tantalum Clip (E5381 854) and Double Tantalum Clip (E5381 853). Overall length: 7.2 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
2 mm x 0.75 mm. Overall length: 125 mm, 4.9 inches....
...
Medicine Products: